Tyvaso and Joint effusion - a phase IV clinical study of FDA data

Summary:

Joint effusion is reported only by a few people who take Tyvaso.

The phase IV clinical study analyzes which people take Tyvaso and have Joint effusion. It is created by eHealthMe based on reports of 32,955 people who have side effects while taking Tyvaso from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 03, 2022

32,955 people reported to have side effects when taking Tyvaso.
Among them, 4 people (0.01%) have Joint effusion.


What is Tyvaso?

Tyvaso has active ingredients of treprostinil sodium. eHealthMe is studying from 32,973 Tyvaso users for its effectiveness, alternative drugs and more.

What is Joint effusion?

Joint effusion (presence of extra fluid in joint covering) is found to be associated with 1,287 drugs and 705 conditions by eHealthMe.

Number of Tyvaso and Joint effusion reports submitted per year:

Could Tyvaso cause Joint effusion?

Gender of people who have Joint effusion when taking Tyvaso *:

  • female: 50 %
  • male: 50 %

Age of people who have Joint effusion when taking Tyvaso *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 75 %
  • 60+: 25 %

Common drugs people take besides Tyvaso *:

  1. Voltaren: 2 people, 50.00%
  2. Symbicort: 2 people, 50.00%
  3. Spiriva: 2 people, 50.00%
  4. Revatio: 2 people, 50.00%
  5. Premarin: 2 people, 50.00%
  6. Phenergan: 2 people, 50.00%
  7. Macitentan: 2 people, 50.00%
  8. Klor-Con: 2 people, 50.00%
  9. Fosamax: 2 people, 50.00%
  10. Cellcept: 2 people, 50.00%

Common side effects people have besides Joint effusion *:

  1. Oxygen Saturation Decreased: 3 people, 75.00%
  2. Pneumonia: 3 people, 75.00%
  3. Oedema (fluid collection in tissue): 3 people, 75.00%
  4. Feeling Abnormal: 3 people, 75.00%
  5. Cardiac Failure Congestive: 3 people, 75.00%
  6. Urinary Tract Infection: 2 people, 50.00%
  7. Joint Pain: 2 people, 50.00%
  8. Nasopharyngitis (inflammation of the nasopharynx): 2 people, 50.00%
  9. Oedema Peripheral (superficial swelling): 2 people, 50.00%
  10. Orthopnea (shortness of breath (dyspnea) when lying down): 2 people, 50.00%

Common conditions people have *:

  1. Pulmonary Hypertension (increase in blood pressure in the lung artery): 3 people, 75.00%
  2. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Tyvaso and have Joint effusion?

Check whether Joint effusion is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Joint effusion and when was it recovered:

Expand to all the drugs that have ingredients of treprostinil sodium:

Alternative drugs to, pros and cons of Tyvaso:

Common Tyvaso side effects:

Browse all side effects of Tyvaso:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Joint effusion treatments and more:

COVID vaccines that are related to Joint effusion:

Common drugs associated with Joint effusion:

All the drugs that are associated with Joint effusion:

Common conditions associated with Joint effusion:

All the conditions that are associated with Joint effusion:

How the study uses the data?

The study uses data from the FDA. It is based on treprostinil sodium (the active ingredients of Tyvaso) and Tyvaso (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: